The company cited patient safety concerns and the current strains on hospitals as the reasons for the postponements.
News & Analysis: NextCure Inc
Nextcure's solid footing should sustain it despite Eli Lilly's decision to walk away from an R&D pact.
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
The recent volatility hasn't been ideal, but it has certainly put the newly public company on the radar of investors.
Walgreens rose on a report of a buyout offer while NextCure gave up some of last week's huge gains.
Highly anticipated clinical trial results didn't continue a promising trend from a smaller number of patients.
Good news from an extremely small number of patients led to Tuesday's enormous bump.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.